MXPA02007543A - Biarilcarboxamidas novedosas. - Google Patents
Biarilcarboxamidas novedosas.Info
- Publication number
- MXPA02007543A MXPA02007543A MXPA02007543A MXPA02007543A MXPA02007543A MX PA02007543 A MXPA02007543 A MX PA02007543A MX PA02007543 A MXPA02007543 A MX PA02007543A MX PA02007543 A MXPA02007543 A MX PA02007543A MX PA02007543 A MXPA02007543 A MX PA02007543A
- Authority
- MX
- Mexico
- Prior art keywords
- oct
- azabicyclo
- carboxamide
- thiophene
- furan
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 346
- 238000000034 method Methods 0.000 claims abstract description 98
- 150000003839 salts Chemical class 0.000 claims abstract description 82
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 57
- 239000001301 oxygen Substances 0.000 claims abstract description 57
- 125000003118 aryl group Chemical group 0.000 claims abstract description 55
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 54
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 51
- 150000002367 halogens Chemical class 0.000 claims abstract description 46
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract description 40
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 39
- 125000001424 substituent group Chemical group 0.000 claims abstract description 37
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 35
- 125000004434 sulfur atom Chemical group 0.000 claims abstract description 30
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 25
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 24
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 24
- 239000011593 sulfur Substances 0.000 claims abstract description 24
- 238000011282 treatment Methods 0.000 claims abstract description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 23
- 239000001257 hydrogen Substances 0.000 claims abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 claims abstract description 16
- 238000011321 prophylaxis Methods 0.000 claims abstract description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 230000008569 process Effects 0.000 claims abstract description 12
- 230000006735 deficit Effects 0.000 claims abstract description 9
- 125000003226 pyrazolyl group Chemical group 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 5
- 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 claims abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 4
- 208000028017 Psychotic disease Diseases 0.000 claims abstract 2
- -1 C-4 alkenyl Chemical group 0.000 claims description 170
- 238000006243 chemical reaction Methods 0.000 claims description 112
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 63
- 239000002904 solvent Substances 0.000 claims description 60
- 229910052757 nitrogen Inorganic materials 0.000 claims description 36
- 239000003054 catalyst Substances 0.000 claims description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 27
- 125000002524 organometallic group Chemical group 0.000 claims description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 claims description 22
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 20
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 150000001408 amides Chemical class 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims description 10
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims description 10
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 10
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 8
- 150000003857 carboxamides Chemical class 0.000 claims description 8
- MVAUXTNBWFARSQ-HNNXBMFYSA-N 5-(3-aminophenyl)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]furan-2-carboxamide Chemical compound NC1=CC=CC(C=2OC(=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 MVAUXTNBWFARSQ-HNNXBMFYSA-N 0.000 claims description 7
- HPLGXOSWRUEUNI-HNNXBMFYSA-N 5-(3-aminophenyl)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thiophene-2-carboxamide Chemical compound NC1=CC=CC(C=2SC(=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 HPLGXOSWRUEUNI-HNNXBMFYSA-N 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- TVFIYRKPCACCNL-UHFFFAOYSA-N furan-2-carboxamide Chemical compound NC(=O)C1=CC=CO1 TVFIYRKPCACCNL-UHFFFAOYSA-N 0.000 claims description 7
- CRXXTGJTHQIACI-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(3-chlorophenyl)furan-2-carboxamide Chemical compound ClC1=CC=CC(C=2OC(=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 CRXXTGJTHQIACI-HNNXBMFYSA-N 0.000 claims description 7
- LCGCTFJMVXHREJ-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(3-hydroxyphenyl)thiophene-2-carboxamide Chemical compound OC1=CC=CC(C=2SC(=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 LCGCTFJMVXHREJ-HNNXBMFYSA-N 0.000 claims description 7
- ZYVHCJHMRMAHSR-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-[3-(trifluoromethyl)phenyl]furan-2-carboxamide Chemical compound FC(F)(F)C1=CC=CC(C=2OC(=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 ZYVHCJHMRMAHSR-HNNXBMFYSA-N 0.000 claims description 7
- FPIGGZJRNAPCBW-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-pyridin-3-ylthiophene-2-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(S1)=CC=C1C1=CC=CN=C1 FPIGGZJRNAPCBW-AWEZNQCLSA-N 0.000 claims description 7
- 229960002715 nicotine Drugs 0.000 claims description 7
- ONRPCVPDQHMEQB-KRWDZBQOSA-N 5-(3-acetamidophenyl)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]thiophene-2-carboxamide Chemical compound CC(=O)NC1=CC=CC(C=2SC(=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 ONRPCVPDQHMEQB-KRWDZBQOSA-N 0.000 claims description 6
- CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical compound NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 claims description 6
- FZDZHQNLYQWDSJ-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(3-cyanophenyl)thiophene-2-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(S1)=CC=C1C1=CC=CC(C#N)=C1 FZDZHQNLYQWDSJ-INIZCTEOSA-N 0.000 claims description 6
- OIEAJUFPEQIZHL-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(3-fluorophenyl)furan-2-carboxamide Chemical compound FC1=CC=CC(C=2OC(=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 OIEAJUFPEQIZHL-HNNXBMFYSA-N 0.000 claims description 6
- GALYCJSQLYPAQX-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(3-methoxyphenyl)thiophene-2-carboxamide Chemical compound COC1=CC=CC(C=2SC(=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 GALYCJSQLYPAQX-INIZCTEOSA-N 0.000 claims description 6
- WAQIEMFSGRAXDS-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(4-fluorophenyl)furan-2-carboxamide Chemical compound C1=CC(F)=CC=C1C1=CC=C(C(=O)N[C@@H]2C3CCN(CC3)C2)O1 WAQIEMFSGRAXDS-HNNXBMFYSA-N 0.000 claims description 6
- RIYNGPMSCLNGPX-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-phenoxythiophene-2-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(S1)=CC=C1OC1=CC=CC=C1 RIYNGPMSCLNGPX-HNNXBMFYSA-N 0.000 claims description 6
- LGYGWEZFGJYJBD-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-pyridin-3-ylfuran-2-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(O1)=CC=C1C1=CC=CN=C1 LGYGWEZFGJYJBD-AWEZNQCLSA-N 0.000 claims description 6
- FMOHTJWWZYDUKQ-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-pyridin-4-ylfuran-2-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(O1)=CC=C1C1=CC=NC=C1 FMOHTJWWZYDUKQ-AWEZNQCLSA-N 0.000 claims description 6
- QDWJHUICASOKIN-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-pyridin-4-ylthiophene-2-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(S1)=CC=C1C1=CC=NC=C1 QDWJHUICASOKIN-AWEZNQCLSA-N 0.000 claims description 6
- UUSSDOJBSVGPEU-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-5-pyridin-2-ylthiophene-2-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(S1)=CC=C1C1=CC=CC=N1 UUSSDOJBSVGPEU-CQSZACIVSA-N 0.000 claims description 6
- FPIGGZJRNAPCBW-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-5-pyridin-3-ylthiophene-2-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(S1)=CC=C1C1=CC=CN=C1 FPIGGZJRNAPCBW-CQSZACIVSA-N 0.000 claims description 6
- MTEMDMUNZYLWSQ-UHFFFAOYSA-N 5-bromothiophene-2-carboxamide Chemical compound NC(=O)C1=CC=C(Br)S1 MTEMDMUNZYLWSQ-UHFFFAOYSA-N 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- CENIOWYLMHMVTC-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-thiophen-3-ylbenzamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C=1)=CC=CC=1C=1C=CSC=1 CENIOWYLMHMVTC-KRWDZBQOSA-N 0.000 claims description 5
- QEIXYTUTAQBVGQ-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-4-phenylthiophene-2-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(SC=1)=CC=1C1=CC=CC=C1 QEIXYTUTAQBVGQ-INIZCTEOSA-N 0.000 claims description 5
- SORHTMNAVSNZNU-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-4-pyridin-2-ylthiophene-2-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(SC=1)=CC=1C1=CC=CC=N1 SORHTMNAVSNZNU-HNNXBMFYSA-N 0.000 claims description 5
- WUKDHJGFJBQDAY-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(3-fluorophenyl)thiophene-2-carboxamide Chemical compound FC1=CC=CC(C=2SC(=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 WUKDHJGFJBQDAY-HNNXBMFYSA-N 0.000 claims description 5
- BJVYZNULTKTECP-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(furan-3-yl)furan-2-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(O1)=CC=C1C=1C=COC=1 BJVYZNULTKTECP-ZDUSSCGKSA-N 0.000 claims description 5
- DUMIUMCPYFQUAA-IBGZPJMESA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-naphthalen-2-ylfuran-2-carboxamide Chemical compound C1=CC=CC2=CC(C3=CC=C(O3)C(N[C@@H]3C4CCN(CC4)C3)=O)=CC=C21 DUMIUMCPYFQUAA-IBGZPJMESA-N 0.000 claims description 5
- KMILHXLZVLODQX-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-pyridin-2-ylfuran-2-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(O1)=CC=C1C1=CC=CC=N1 KMILHXLZVLODQX-AWEZNQCLSA-N 0.000 claims description 5
- UUSSDOJBSVGPEU-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-pyridin-2-ylthiophene-2-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(S1)=CC=C1C1=CC=CC=N1 UUSSDOJBSVGPEU-AWEZNQCLSA-N 0.000 claims description 5
- GVYLEUINEJZIHU-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-pyridin-3-ylthiophene-3-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C=1)=CSC=1C1=CC=CN=C1 GVYLEUINEJZIHU-HNNXBMFYSA-N 0.000 claims description 5
- YDOOADJCFORQJS-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-quinolin-8-ylthiophene-2-carboxamide Chemical compound C1=CN=C2C(C3=CC=C(S3)C(N[C@@H]3C4CCN(CC4)C3)=O)=CC=CC2=C1 YDOOADJCFORQJS-KRWDZBQOSA-N 0.000 claims description 5
- LFGBLTXCNGFMSZ-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-thiophen-3-ylfuran-2-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(O1)=CC=C1C=1C=CSC=1 LFGBLTXCNGFMSZ-ZDUSSCGKSA-N 0.000 claims description 5
- LEUSUHAAYXEGAO-OAHLLOKOSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-5-phenylthiophene-2-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(S1)=CC=C1C1=CC=CC=C1 LEUSUHAAYXEGAO-OAHLLOKOSA-N 0.000 claims description 5
- 150000002902 organometallic compounds Chemical class 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 4
- MEXOEXAUFQFSTA-KRWDZBQOSA-N 5-(3-acetamidophenyl)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]furan-2-carboxamide Chemical compound CC(=O)NC1=CC=CC(C=2OC(=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 MEXOEXAUFQFSTA-KRWDZBQOSA-N 0.000 claims description 4
- VFDAOWISEQYGIF-UHFFFAOYSA-N 5-bromofuran-2-carboxamide Chemical compound NC(=O)C1=CC=C(Br)O1 VFDAOWISEQYGIF-UHFFFAOYSA-N 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 230000006866 deterioration Effects 0.000 claims description 4
- MQDUBMOSAYRTMJ-IBGZPJMESA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-phenylbenzamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C=1)=CC=CC=1C1=CC=CC=C1 MQDUBMOSAYRTMJ-IBGZPJMESA-N 0.000 claims description 4
- XGBYUOBPRHUNDX-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(3,5-dimethyl-1,2-oxazol-4-yl)thiophene-2-carboxamide Chemical compound CC1=NOC(C)=C1C1=CC=C(C(=O)N[C@@H]2C3CCN(CC3)C2)S1 XGBYUOBPRHUNDX-ZDUSSCGKSA-N 0.000 claims description 4
- QTGLVGGNFKMBPR-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(3-chlorophenyl)thiophene-2-carboxamide Chemical compound ClC1=CC=CC(C=2SC(=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 QTGLVGGNFKMBPR-HNNXBMFYSA-N 0.000 claims description 4
- PJOONCNDVDQBAH-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(3-ethoxyphenyl)thiophene-2-carboxamide Chemical compound CCOC1=CC=CC(C=2SC(=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 PJOONCNDVDQBAH-KRWDZBQOSA-N 0.000 claims description 4
- HRHDJQHTJTVUMB-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(3-nitrophenyl)furan-2-carboxamide Chemical compound [O-][N+](=O)C1=CC=CC(C=2OC(=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 HRHDJQHTJTVUMB-HNNXBMFYSA-N 0.000 claims description 4
- HHEJZTPFVXRLCP-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(pyridin-3-ylamino)thiophene-2-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(S1)=CC=C1NC1=CC=CN=C1 HHEJZTPFVXRLCP-AWEZNQCLSA-N 0.000 claims description 4
- OWGIBYSBTRBKPD-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-[3-(dimethylamino)phenyl]furan-2-carboxamide Chemical compound CN(C)C1=CC=CC(C=2OC(=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 OWGIBYSBTRBKPD-KRWDZBQOSA-N 0.000 claims description 4
- IPNOSOBDTLDLNU-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-[3-(dimethylamino)phenyl]thiophene-2-carboxamide Chemical compound CN(C)C1=CC=CC(C=2SC(=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 IPNOSOBDTLDLNU-KRWDZBQOSA-N 0.000 claims description 4
- TYPDWKBLNJSIHR-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-[3-(hydroxymethyl)phenyl]thiophene-2-carboxamide Chemical compound OCC1=CC=CC(C=2SC(=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 TYPDWKBLNJSIHR-INIZCTEOSA-N 0.000 claims description 4
- XXXRVCPQJSWEIQ-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-phenylfuran-2-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(O1)=CC=C1C1=CC=CC=C1 XXXRVCPQJSWEIQ-HNNXBMFYSA-N 0.000 claims description 4
- LEUSUHAAYXEGAO-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-phenylthiophene-2-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(S1)=CC=C1C1=CC=CC=C1 LEUSUHAAYXEGAO-HNNXBMFYSA-N 0.000 claims description 4
- NKPRIPDEFRADKU-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-phenylthiophene-3-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C=1)=CSC=1C1=CC=CC=C1 NKPRIPDEFRADKU-INIZCTEOSA-N 0.000 claims description 4
- ZFFGQNHUUBRDTF-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-thiophen-2-ylfuran-2-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(O1)=CC=C1C1=CC=CS1 ZFFGQNHUUBRDTF-LBPRGKRZSA-N 0.000 claims description 4
- QDWJHUICASOKIN-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-5-pyridin-4-ylthiophene-2-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(S1)=CC=C1C1=CC=NC=C1 QDWJHUICASOKIN-CQSZACIVSA-N 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- ODJFDWIECLJWSR-UHFFFAOYSA-N 3-bromobenzamide Chemical compound NC(=O)C1=CC=CC(Br)=C1 ODJFDWIECLJWSR-UHFFFAOYSA-N 0.000 claims description 3
- WPIFYCRDSOUHLT-UHFFFAOYSA-N 4-bromothiophene-2-carboxamide Chemical compound NC(=O)C1=CC(Br)=CS1 WPIFYCRDSOUHLT-UHFFFAOYSA-N 0.000 claims description 3
- XRNBLQCAFWFFPM-UHFFFAOYSA-N 4-iodobenzamide Chemical compound NC(=O)C1=CC=C(I)C=C1 XRNBLQCAFWFFPM-UHFFFAOYSA-N 0.000 claims description 3
- GFHNPIHLDMSUBY-UHFFFAOYSA-N 5-(3-methoxyphenyl)furan-2-carboxamide Chemical compound COC1=CC=CC(C=2OC(=CC=2)C(N)=O)=C1 GFHNPIHLDMSUBY-UHFFFAOYSA-N 0.000 claims description 3
- XTPWJBLYVBMEQX-UHFFFAOYSA-N 5-(4-chlorophenyl)furan-2-carboxamide Chemical compound O1C(C(=O)N)=CC=C1C1=CC=C(Cl)C=C1 XTPWJBLYVBMEQX-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 3
- 208000016620 Tourette disease Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- QDWJHUICASOKIN-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-pyridin-4-ylthiophene-2-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(S1)=CC=C1C1=CC=NC=C1 QDWJHUICASOKIN-UHFFFAOYSA-N 0.000 claims description 3
- CAGKKXJJWGYHAV-QHCPKHFHSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-naphthalen-2-ylbenzamide Chemical compound C1=CC=CC2=CC(C=3C=CC=C(C=3)C(N[C@@H]3C4CCN(CC4)C3)=O)=CC=C21 CAGKKXJJWGYHAV-QHCPKHFHSA-N 0.000 claims description 3
- GLNKFTQXNCWCSJ-SFHVURJKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-pyridin-3-ylbenzamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C=1)=CC=CC=1C1=CC=CN=C1 GLNKFTQXNCWCSJ-SFHVURJKSA-N 0.000 claims description 3
- NWJHCFDCWWUKAS-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-thiophen-2-ylbenzamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C=1)=CC=CC=1C1=CC=CS1 NWJHCFDCWWUKAS-INIZCTEOSA-N 0.000 claims description 3
- CCJXUEWABMMONA-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-4-pyridin-3-ylthiophene-2-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(SC=1)=CC=1C1=CC=CN=C1 CCJXUEWABMMONA-HNNXBMFYSA-N 0.000 claims description 3
- NDEVYBGGPPDEPG-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-4-pyridin-4-ylthiophene-2-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(SC=1)=CC=1C1=CC=NC=C1 NDEVYBGGPPDEPG-HNNXBMFYSA-N 0.000 claims description 3
- LIPAWTBPKLAATH-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(1-benzofuran-2-yl)furan-2-carboxamide Chemical compound C1=CC=C2OC(C3=CC=C(O3)C(N[C@@H]3C4CCN(CC4)C3)=O)=CC2=C1 LIPAWTBPKLAATH-HNNXBMFYSA-N 0.000 claims description 3
- XKKZIJRJJSXKPX-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(3,5-dimethyl-1,2-oxazol-4-yl)furan-2-carboxamide Chemical compound CC1=NOC(C)=C1C1=CC=C(C(=O)N[C@@H]2C3CCN(CC3)C2)O1 XKKZIJRJJSXKPX-ZDUSSCGKSA-N 0.000 claims description 3
- FEKRXODBAGHYRA-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(3-methoxyphenyl)furan-2-carboxamide Chemical compound COC1=CC=CC(C=2OC(=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 FEKRXODBAGHYRA-INIZCTEOSA-N 0.000 claims description 3
- RFMVCNKMEMIOTJ-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(3-methylphenyl)furan-2-carboxamide Chemical compound CC1=CC=CC(C=2OC(=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 RFMVCNKMEMIOTJ-INIZCTEOSA-N 0.000 claims description 3
- IUYIHWNTJKCXNG-IBGZPJMESA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(3-morpholin-4-ylphenyl)thiophene-2-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(S1)=CC=C1C(C=1)=CC=CC=1N1CCOCC1 IUYIHWNTJKCXNG-IBGZPJMESA-N 0.000 claims description 3
- SXYCOKGWVCJBTB-LBPRGKRZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(furan-2-yl)furan-2-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(O1)=CC=C1C1=CC=CO1 SXYCOKGWVCJBTB-LBPRGKRZSA-N 0.000 claims description 3
- HXCRNIZEZKEKNY-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-pyridin-3-yl-2h-1,3-thiazole-3-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)N(C=1)CSC=1C1=CC=CN=C1 HXCRNIZEZKEKNY-AWEZNQCLSA-N 0.000 claims description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- FGIMLEOUWYBPNF-UHFFFAOYSA-N 2-(2-methoxyphenyl)benzamide Chemical compound COC1=CC=CC=C1C1=CC=CC=C1C(N)=O FGIMLEOUWYBPNF-UHFFFAOYSA-N 0.000 claims description 2
- FYNUJNYNUVOPQU-UHFFFAOYSA-N 2-(3-fluorophenyl)benzamide Chemical compound NC(=O)C1=CC=CC=C1C1=CC=CC(F)=C1 FYNUJNYNUVOPQU-UHFFFAOYSA-N 0.000 claims description 2
- UKVIXOCFJKWXSA-UHFFFAOYSA-N 2-(3-methoxyphenyl)benzamide Chemical compound COC1=CC=CC(C=2C(=CC=CC=2)C(N)=O)=C1 UKVIXOCFJKWXSA-UHFFFAOYSA-N 0.000 claims description 2
- OTNOXWBLYHUWLZ-NRFANRHFSA-N 3-(3-acetamidophenyl)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]benzamide Chemical compound CC(=O)NC1=CC=CC(C=2C=C(C=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 OTNOXWBLYHUWLZ-NRFANRHFSA-N 0.000 claims description 2
- HEMYUAPEXJWFCP-UHFFFAOYSA-N 3-iodobenzamide Chemical compound NC(=O)C1=CC=CC(I)=C1 HEMYUAPEXJWFCP-UHFFFAOYSA-N 0.000 claims description 2
- ZRWNRAJCPNLYAK-UHFFFAOYSA-N 4-bromobenzamide Chemical compound NC(=O)C1=CC=C(Br)C=C1 ZRWNRAJCPNLYAK-UHFFFAOYSA-N 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- MEXOEXAUFQFSTA-UHFFFAOYSA-N 5-(3-acetamidophenyl)-n-(1-azabicyclo[2.2.2]octan-3-yl)furan-2-carboxamide Chemical compound CC(=O)NC1=CC=CC(C=2OC(=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 MEXOEXAUFQFSTA-UHFFFAOYSA-N 0.000 claims description 2
- ONRPCVPDQHMEQB-UHFFFAOYSA-N 5-(3-acetamidophenyl)-n-(1-azabicyclo[2.2.2]octan-3-yl)thiophene-2-carboxamide Chemical compound CC(=O)NC1=CC=CC(C=2SC(=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 ONRPCVPDQHMEQB-UHFFFAOYSA-N 0.000 claims description 2
- MVAUXTNBWFARSQ-UHFFFAOYSA-N 5-(3-aminophenyl)-n-(1-azabicyclo[2.2.2]octan-3-yl)furan-2-carboxamide Chemical compound NC1=CC=CC(C=2OC(=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 MVAUXTNBWFARSQ-UHFFFAOYSA-N 0.000 claims description 2
- HPLGXOSWRUEUNI-UHFFFAOYSA-N 5-(3-aminophenyl)-n-(1-azabicyclo[2.2.2]octan-3-yl)thiophene-2-carboxamide Chemical compound NC1=CC=CC(C=2SC(=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 HPLGXOSWRUEUNI-UHFFFAOYSA-N 0.000 claims description 2
- ZTOXUTFUEKVQNM-UHFFFAOYSA-N 5-(3-cyanophenyl)thiophene-2-carboxamide Chemical compound S1C(C(=O)N)=CC=C1C1=CC=CC(C#N)=C1 ZTOXUTFUEKVQNM-UHFFFAOYSA-N 0.000 claims description 2
- FPASADMLLORPAS-UHFFFAOYSA-N 5-(3-nitrophenyl)furan-2-carboxamide Chemical compound O1C(C(=O)N)=CC=C1C1=CC=CC([N+]([O-])=O)=C1 FPASADMLLORPAS-UHFFFAOYSA-N 0.000 claims description 2
- ISXKVVQBTQEGSI-UHFFFAOYSA-N 5-bromothiophene-3-carboxamide Chemical compound NC(=O)C1=CSC(Br)=C1 ISXKVVQBTQEGSI-UHFFFAOYSA-N 0.000 claims description 2
- 208000000044 Amnesia Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 2
- 201000002832 Lewy body dementia Diseases 0.000 claims description 2
- 206010026749 Mania Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 125000003047 N-acetyl group Chemical group 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 208000028683 bipolar I disease Diseases 0.000 claims description 2
- 230000001713 cholinergic effect Effects 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 230000006984 memory degeneration Effects 0.000 claims description 2
- 208000023060 memory loss Diseases 0.000 claims description 2
- WTUHRGRJMXKQOM-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(3,5-dichlorophenyl)benzamide Chemical compound ClC1=CC(Cl)=CC(C=2C=C(C=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 WTUHRGRJMXKQOM-UHFFFAOYSA-N 0.000 claims description 2
- BHVNSJHUVOVCMX-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(3-fluorophenyl)benzamide Chemical compound FC1=CC=CC(C=2C=C(C=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 BHVNSJHUVOVCMX-UHFFFAOYSA-N 0.000 claims description 2
- VTRZFLGHZHXPNK-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(3-methylphenyl)benzamide Chemical compound CC1=CC=CC(C=2C=C(C=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 VTRZFLGHZHXPNK-UHFFFAOYSA-N 0.000 claims description 2
- CLUDFFGNGQDYJV-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-fluorophenyl)benzamide Chemical compound C1=CC(F)=CC=C1C1=CC=CC(C(=O)NC2C3CCN(CC3)C2)=C1 CLUDFFGNGQDYJV-UHFFFAOYSA-N 0.000 claims description 2
- CAGKKXJJWGYHAV-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-3-naphthalen-2-ylbenzamide Chemical compound C1=CC=CC2=CC(C=3C=CC=C(C=3)C(NC3C4CCN(CC4)C3)=O)=CC=C21 CAGKKXJJWGYHAV-UHFFFAOYSA-N 0.000 claims description 2
- MQDUBMOSAYRTMJ-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-3-phenylbenzamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(C=1)=CC=CC=1C1=CC=CC=C1 MQDUBMOSAYRTMJ-UHFFFAOYSA-N 0.000 claims description 2
- NWJHCFDCWWUKAS-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-3-thiophen-2-ylbenzamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(C=1)=CC=CC=1C1=CC=CS1 NWJHCFDCWWUKAS-UHFFFAOYSA-N 0.000 claims description 2
- CENIOWYLMHMVTC-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-3-thiophen-3-ylbenzamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(C=1)=CC=CC=1C=1C=CSC=1 CENIOWYLMHMVTC-UHFFFAOYSA-N 0.000 claims description 2
- SORHTMNAVSNZNU-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-4-pyridin-2-ylthiophene-2-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(SC=1)=CC=1C1=CC=CC=N1 SORHTMNAVSNZNU-UHFFFAOYSA-N 0.000 claims description 2
- CCJXUEWABMMONA-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-4-pyridin-3-ylthiophene-2-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(SC=1)=CC=1C1=CC=CN=C1 CCJXUEWABMMONA-UHFFFAOYSA-N 0.000 claims description 2
- MUAPAJCASHAKDD-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-(2-methoxyphenyl)furan-2-carboxamide Chemical compound COC1=CC=CC=C1C1=CC=C(C(=O)NC2C3CCN(CC3)C2)O1 MUAPAJCASHAKDD-UHFFFAOYSA-N 0.000 claims description 2
- XKKZIJRJJSXKPX-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-(3,5-dimethyl-1,2-oxazol-4-yl)furan-2-carboxamide Chemical compound CC1=NOC(C)=C1C1=CC=C(C(=O)NC2C3CCN(CC3)C2)O1 XKKZIJRJJSXKPX-UHFFFAOYSA-N 0.000 claims description 2
- XGBYUOBPRHUNDX-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-(3,5-dimethyl-1,2-oxazol-4-yl)thiophene-2-carboxamide Chemical compound CC1=NOC(C)=C1C1=CC=C(C(=O)NC2C3CCN(CC3)C2)S1 XGBYUOBPRHUNDX-UHFFFAOYSA-N 0.000 claims description 2
- CRXXTGJTHQIACI-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-(3-chlorophenyl)furan-2-carboxamide Chemical compound ClC1=CC=CC(C=2OC(=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 CRXXTGJTHQIACI-UHFFFAOYSA-N 0.000 claims description 2
- QTGLVGGNFKMBPR-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-(3-chlorophenyl)thiophene-2-carboxamide Chemical compound ClC1=CC=CC(C=2SC(=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 QTGLVGGNFKMBPR-UHFFFAOYSA-N 0.000 claims description 2
- PJOONCNDVDQBAH-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-(3-ethoxyphenyl)thiophene-2-carboxamide Chemical compound CCOC1=CC=CC(C=2SC(=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 PJOONCNDVDQBAH-UHFFFAOYSA-N 0.000 claims description 2
- UWKVRXHHKRDKTN-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-(3-formylphenyl)thiophene-2-carboxamide Chemical compound O=CC1=CC=CC(C=2SC(=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 UWKVRXHHKRDKTN-UHFFFAOYSA-N 0.000 claims description 2
- FEKRXODBAGHYRA-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-(3-methoxyphenyl)furan-2-carboxamide Chemical compound COC1=CC=CC(C=2OC(=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 FEKRXODBAGHYRA-UHFFFAOYSA-N 0.000 claims description 2
- RFMVCNKMEMIOTJ-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-(3-methylphenyl)furan-2-carboxamide Chemical compound CC1=CC=CC(C=2OC(=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 RFMVCNKMEMIOTJ-UHFFFAOYSA-N 0.000 claims description 2
- IUYIHWNTJKCXNG-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-(3-morpholin-4-ylphenyl)thiophene-2-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(S1)=CC=C1C(C=1)=CC=CC=1N1CCOCC1 IUYIHWNTJKCXNG-UHFFFAOYSA-N 0.000 claims description 2
- HRHDJQHTJTVUMB-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-(3-nitrophenyl)furan-2-carboxamide Chemical compound [O-][N+](=O)C1=CC=CC(C=2OC(=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 HRHDJQHTJTVUMB-UHFFFAOYSA-N 0.000 claims description 2
- PFKKVUBNDMRQFB-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-(4-chlorophenyl)furan-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=C(C(=O)NC2C3CCN(CC3)C2)O1 PFKKVUBNDMRQFB-UHFFFAOYSA-N 0.000 claims description 2
- WAQIEMFSGRAXDS-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-(4-fluorophenyl)furan-2-carboxamide Chemical compound C1=CC(F)=CC=C1C1=CC=C(C(=O)NC2C3CCN(CC3)C2)O1 WAQIEMFSGRAXDS-UHFFFAOYSA-N 0.000 claims description 2
- SXYCOKGWVCJBTB-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-(furan-2-yl)furan-2-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(O1)=CC=C1C1=CC=CO1 SXYCOKGWVCJBTB-UHFFFAOYSA-N 0.000 claims description 2
- BJVYZNULTKTECP-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-(furan-3-yl)furan-2-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(O1)=CC=C1C=1C=COC=1 BJVYZNULTKTECP-UHFFFAOYSA-N 0.000 claims description 2
- HHEJZTPFVXRLCP-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-(pyridin-3-ylamino)thiophene-2-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(S1)=CC=C1NC1=CC=CN=C1 HHEJZTPFVXRLCP-UHFFFAOYSA-N 0.000 claims description 2
- OWGIBYSBTRBKPD-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-[3-(dimethylamino)phenyl]furan-2-carboxamide Chemical compound CN(C)C1=CC=CC(C=2OC(=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 OWGIBYSBTRBKPD-UHFFFAOYSA-N 0.000 claims description 2
- ZYVHCJHMRMAHSR-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-[3-(trifluoromethyl)phenyl]furan-2-carboxamide Chemical compound FC(F)(F)C1=CC=CC(C=2OC(=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 ZYVHCJHMRMAHSR-UHFFFAOYSA-N 0.000 claims description 2
- YXUZRNBUKKHHJQ-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-bromothiophene-2-carboxamide Chemical compound S1C(Br)=CC=C1C(=O)NC1C(CC2)CCN2C1 YXUZRNBUKKHHJQ-UHFFFAOYSA-N 0.000 claims description 2
- JEAHJLXHLCBPED-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-bromothiophene-3-carboxamide Chemical compound S1C(Br)=CC(C(=O)NC2C3CCN(CC3)C2)=C1 JEAHJLXHLCBPED-UHFFFAOYSA-N 0.000 claims description 2
- DUMIUMCPYFQUAA-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-naphthalen-2-ylfuran-2-carboxamide Chemical compound C1=CC=CC2=CC(C3=CC=C(O3)C(NC3C4CCN(CC4)C3)=O)=CC=C21 DUMIUMCPYFQUAA-UHFFFAOYSA-N 0.000 claims description 2
- RIYNGPMSCLNGPX-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-phenoxythiophene-2-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(S1)=CC=C1OC1=CC=CC=C1 RIYNGPMSCLNGPX-UHFFFAOYSA-N 0.000 claims description 2
- XXXRVCPQJSWEIQ-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-phenylfuran-2-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(O1)=CC=C1C1=CC=CC=C1 XXXRVCPQJSWEIQ-UHFFFAOYSA-N 0.000 claims description 2
- LEUSUHAAYXEGAO-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-phenylthiophene-2-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(S1)=CC=C1C1=CC=CC=C1 LEUSUHAAYXEGAO-UHFFFAOYSA-N 0.000 claims description 2
- KMILHXLZVLODQX-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-pyridin-2-ylfuran-2-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(O1)=CC=C1C1=CC=CC=N1 KMILHXLZVLODQX-UHFFFAOYSA-N 0.000 claims description 2
- UUSSDOJBSVGPEU-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-pyridin-2-ylthiophene-2-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(S1)=CC=C1C1=CC=CC=N1 UUSSDOJBSVGPEU-UHFFFAOYSA-N 0.000 claims description 2
- FPIGGZJRNAPCBW-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-pyridin-3-ylthiophene-2-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(S1)=CC=C1C1=CC=CN=C1 FPIGGZJRNAPCBW-UHFFFAOYSA-N 0.000 claims description 2
- GVYLEUINEJZIHU-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-pyridin-3-ylthiophene-3-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(C=1)=CSC=1C1=CC=CN=C1 GVYLEUINEJZIHU-UHFFFAOYSA-N 0.000 claims description 2
- ZFFGQNHUUBRDTF-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-thiophen-2-ylfuran-2-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(O1)=CC=C1C1=CC=CS1 ZFFGQNHUUBRDTF-UHFFFAOYSA-N 0.000 claims description 2
- LFGBLTXCNGFMSZ-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-thiophen-3-ylfuran-2-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(O1)=CC=C1C=1C=CSC=1 LFGBLTXCNGFMSZ-UHFFFAOYSA-N 0.000 claims description 2
- MUAPAJCASHAKDD-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(2-methoxyphenyl)furan-2-carboxamide Chemical compound COC1=CC=CC=C1C1=CC=C(C(=O)N[C@@H]2C3CCN(CC3)C2)O1 MUAPAJCASHAKDD-HNNXBMFYSA-N 0.000 claims description 2
- XHIBZIFIARCBMN-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-pyridin-4-yl-2h-1,3-thiazole-3-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)N(C=1)CSC=1C1=CC=NC=C1 XHIBZIFIARCBMN-AWEZNQCLSA-N 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 229930192474 thiophene Natural products 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 101100460844 Mus musculus Nr2f6 gene Proteins 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- IYZIARNSXPGYSC-UHFFFAOYSA-N 3-phenylbenzamide Chemical compound NC(=O)C1=CC=CC(C=2C=CC=CC=2)=C1 IYZIARNSXPGYSC-UHFFFAOYSA-N 0.000 claims 1
- HVUMTDUVKSHFTQ-UHFFFAOYSA-N 5-(3-fluorophenyl)furan-2-carboxamide Chemical compound O1C(C(=O)N)=CC=C1C1=CC=CC(F)=C1 HVUMTDUVKSHFTQ-UHFFFAOYSA-N 0.000 claims 1
- BZFMDQZSQUUFQS-UHFFFAOYSA-N 5-(3-formylphenyl)thiophene-2-carboxamide Chemical compound C(=O)C=1C=C(C=CC1)C1=CC=C(S1)C(=O)N BZFMDQZSQUUFQS-UHFFFAOYSA-N 0.000 claims 1
- LQSYOLVFFWKQRW-UHFFFAOYSA-N 5-(3-hydroxyphenyl)thiophene-2-carboxamide Chemical compound S1C(C(=O)N)=CC=C1C1=CC=CC(O)=C1 LQSYOLVFFWKQRW-UHFFFAOYSA-N 0.000 claims 1
- VAUBKXFQQWAVRK-UHFFFAOYSA-N 5-(3-methoxyphenyl)thiophene-2-carboxamide Chemical compound COC1=CC=CC(C=2SC(=CC=2)C(N)=O)=C1 VAUBKXFQQWAVRK-UHFFFAOYSA-N 0.000 claims 1
- RQJWFHRUPTYLOV-UHFFFAOYSA-N 5-(3-methylphenyl)furan-2-carboxamide Chemical compound CC1=CC=CC(C=2OC(=CC=2)C(N)=O)=C1 RQJWFHRUPTYLOV-UHFFFAOYSA-N 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 125000004188 dichlorophenyl group Chemical group 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- UVLJDZIZYSDTKE-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(3-methoxyphenyl)benzamide Chemical compound COC1=CC=CC(C=2C=C(C=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 UVLJDZIZYSDTKE-UHFFFAOYSA-N 0.000 claims 1
- RWRRNEWYRHYZAK-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-3-iodobenzamide Chemical compound IC1=CC=CC(C(=O)NC2C3CCN(CC3)C2)=C1 RWRRNEWYRHYZAK-UHFFFAOYSA-N 0.000 claims 1
- GLNKFTQXNCWCSJ-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-3-pyridin-3-ylbenzamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(C=1)=CC=CC=1C1=CC=CN=C1 GLNKFTQXNCWCSJ-UHFFFAOYSA-N 0.000 claims 1
- BXVSCDNQMVRJHW-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-4-bromobenzamide Chemical compound C1=CC(Br)=CC=C1C(=O)NC1C(CC2)CCN2C1 BXVSCDNQMVRJHW-UHFFFAOYSA-N 0.000 claims 1
- XHIBZIFIARCBMN-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-pyridin-4-yl-2h-1,3-thiazole-3-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)N(C=1)CSC=1C1=CC=NC=C1 XHIBZIFIARCBMN-UHFFFAOYSA-N 0.000 claims 1
- PFKKVUBNDMRQFB-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(4-chlorophenyl)furan-2-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=C(C(=O)N[C@@H]2C3CCN(CC3)C2)O1 PFKKVUBNDMRQFB-HNNXBMFYSA-N 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 230000007470 synaptic degeneration Effects 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 240
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 195
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 184
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 128
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 112
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 106
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 104
- 239000000203 mixture Substances 0.000 description 101
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 96
- 239000000243 solution Substances 0.000 description 87
- 239000003480 eluent Substances 0.000 description 85
- 239000007787 solid Substances 0.000 description 80
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 75
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 71
- 239000000047 product Substances 0.000 description 67
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 66
- 238000001704 evaporation Methods 0.000 description 65
- 239000003643 water by type Substances 0.000 description 65
- 238000004007 reversed phase HPLC Methods 0.000 description 63
- 229960004132 diethyl ether Drugs 0.000 description 61
- 239000002585 base Substances 0.000 description 48
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 47
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 47
- 230000008020 evaporation Effects 0.000 description 47
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 37
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 37
- 229910000029 sodium carbonate Inorganic materials 0.000 description 35
- 239000003446 ligand Substances 0.000 description 33
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 30
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 28
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 26
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 26
- 238000001953 recrystallisation Methods 0.000 description 24
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 22
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical class [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 22
- NRTUMYGDHDVGNW-VIFPVBQESA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-bromofuran-2-carboxamide Chemical compound O1C(Br)=CC=C1C(=O)N[C@@H]1C(CC2)CCN2C1 NRTUMYGDHDVGNW-VIFPVBQESA-N 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000000543 intermediate Substances 0.000 description 21
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 20
- 239000012442 inert solvent Substances 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000002253 acid Substances 0.000 description 18
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 15
- 229910000024 caesium carbonate Inorganic materials 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- YXUZRNBUKKHHJQ-VIFPVBQESA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-bromothiophene-2-carboxamide Chemical compound S1C(Br)=CC=C1C(=O)N[C@@H]1C(CC2)CCN2C1 YXUZRNBUKKHHJQ-VIFPVBQESA-N 0.000 description 15
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 14
- 239000007822 coupling agent Substances 0.000 description 14
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 13
- 238000003818 flash chromatography Methods 0.000 description 13
- DAWFSECLBKZUHN-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-bromobenzamide Chemical compound BrC1=CC=CC(C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 DAWFSECLBKZUHN-ZDUSSCGKSA-N 0.000 description 13
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- 230000010933 acylation Effects 0.000 description 12
- 238000005917 acylation reaction Methods 0.000 description 12
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 12
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 12
- 229910052708 sodium Inorganic materials 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- 239000004210 ether based solvent Substances 0.000 description 11
- 229960000583 acetic acid Drugs 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 8
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 8
- 229910052783 alkali metal Inorganic materials 0.000 description 7
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 7
- 101100240516 Caenorhabditis elegans nhr-10 gene Proteins 0.000 description 6
- 239000004215 Carbon black (E152) Substances 0.000 description 6
- 125000005620 boronic acid group Chemical class 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 229930195733 hydrocarbon Natural products 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 6
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 5
- GRTJBNJOHNTQBO-UHFFFAOYSA-N [2-(2-diphenylphosphanylphenyl)phenyl]-diphenylphosphane Chemical group C1=CC=CC=C1P(C=1C(=CC=CC=1)C=1C(=CC=CC=1)P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 GRTJBNJOHNTQBO-UHFFFAOYSA-N 0.000 description 5
- 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 description 5
- 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 238000005804 alkylation reaction Methods 0.000 description 5
- 150000001718 carbodiimides Chemical class 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- OFMXVWXJUWNVGE-JTQLQIEISA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-4-bromothiophene-2-carboxamide Chemical compound BrC1=CSC(C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 OFMXVWXJUWNVGE-JTQLQIEISA-N 0.000 description 5
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 125000005500 uronium group Chemical group 0.000 description 5
- REUAXQZIRFXQML-ZETCQYMHSA-N (3r)-1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1CC2[C@@H](N)CN1CC2 REUAXQZIRFXQML-ZETCQYMHSA-N 0.000 description 4
- 229930182840 (S)-nicotine Natural products 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 230000029936 alkylation Effects 0.000 description 4
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 4
- 229910001863 barium hydroxide Inorganic materials 0.000 description 4
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 150000002431 hydrogen Chemical group 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- YXUZRNBUKKHHJQ-SECBINFHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-5-bromothiophene-2-carboxamide Chemical compound S1C(Br)=CC=C1C(=O)N[C@H]1C(CC2)CCN2C1 YXUZRNBUKKHHJQ-SECBINFHSA-N 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 4
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- GYUURHMITDQTRU-UHFFFAOYSA-N tributyl(pyridin-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CC=N1 GYUURHMITDQTRU-UHFFFAOYSA-N 0.000 description 4
- BPLUKJNHPBNVQL-UHFFFAOYSA-N triphenylarsine Chemical compound C1=CC=CC=C1[As](C=1C=CC=CC=1)C1=CC=CC=C1 BPLUKJNHPBNVQL-UHFFFAOYSA-N 0.000 description 4
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical class [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 3
- 150000008041 alkali metal carbonates Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
- 239000003849 aromatic solvent Substances 0.000 description 3
- 150000001502 aryl halides Chemical class 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- ROEQGIFOWRQYHD-UHFFFAOYSA-N (2-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC=C1B(O)O ROEQGIFOWRQYHD-UHFFFAOYSA-N 0.000 description 2
- SDEAGACSNFSZCU-UHFFFAOYSA-N (3-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Cl)=C1 SDEAGACSNFSZCU-UHFFFAOYSA-N 0.000 description 2
- KNXQDJCZSVHEIW-UHFFFAOYSA-N (3-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(F)=C1 KNXQDJCZSVHEIW-UHFFFAOYSA-N 0.000 description 2
- BJQCPCFFYBKRLM-UHFFFAOYSA-N (3-methylphenyl)boronic acid Chemical compound CC1=CC=CC(B(O)O)=C1 BJQCPCFFYBKRLM-UHFFFAOYSA-N 0.000 description 2
- STZHBULOYDCZET-KLXURFKVSA-N (3r)-1-azabicyclo[2.2.2]octan-3-amine;dihydrochloride Chemical compound Cl.Cl.C1CC2[C@@H](N)CN1CC2 STZHBULOYDCZET-KLXURFKVSA-N 0.000 description 2
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- HJZFPRVFLBBAMU-UHFFFAOYSA-N 4-bromothiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC(Br)=CS1 HJZFPRVFLBBAMU-UHFFFAOYSA-N 0.000 description 2
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 2
- COWZPSUDTMGBAT-UHFFFAOYSA-N 5-bromothiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(Br)S1 COWZPSUDTMGBAT-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- BHMZHLVLASSMIX-UHFFFAOYSA-N COC1=CC=C(C=C1)S[PH2]=S Chemical class COC1=CC=C(C=C1)S[PH2]=S BHMZHLVLASSMIX-UHFFFAOYSA-N 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
- 239000003377 acid catalyst Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052792 caesium Inorganic materials 0.000 description 2
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- QEIXYTUTAQBVGQ-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-4-phenylthiophene-2-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(SC=1)=CC=1C1=CC=CC=C1 QEIXYTUTAQBVGQ-UHFFFAOYSA-N 0.000 description 2
- WTUHRGRJMXKQOM-IBGZPJMESA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(3,5-dichlorophenyl)benzamide Chemical compound ClC1=CC(Cl)=CC(C=2C=C(C=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 WTUHRGRJMXKQOM-IBGZPJMESA-N 0.000 description 2
- CLUDFFGNGQDYJV-IBGZPJMESA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(4-fluorophenyl)benzamide Chemical compound C1=CC(F)=CC=C1C1=CC=CC(C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 CLUDFFGNGQDYJV-IBGZPJMESA-N 0.000 description 2
- RWRRNEWYRHYZAK-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-iodobenzamide Chemical compound IC1=CC=CC(C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 RWRRNEWYRHYZAK-ZDUSSCGKSA-N 0.000 description 2
- BXVSCDNQMVRJHW-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-4-bromobenzamide Chemical compound C1=CC(Br)=CC=C1C(=O)N[C@@H]1C(CC2)CCN2C1 BXVSCDNQMVRJHW-ZDUSSCGKSA-N 0.000 description 2
- UWKVRXHHKRDKTN-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(3-formylphenyl)thiophene-2-carboxamide Chemical compound O=CC1=CC=CC(C=2SC(=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 UWKVRXHHKRDKTN-INIZCTEOSA-N 0.000 description 2
- INHFORKYPSDFNF-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-[3-(methylamino)phenyl]thiophene-2-carboxamide Chemical compound CNC1=CC=CC(C=2SC(=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 INHFORKYPSDFNF-INIZCTEOSA-N 0.000 description 2
- JEAHJLXHLCBPED-JTQLQIEISA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-bromothiophene-3-carboxamide Chemical compound S1C(Br)=CC(C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 JEAHJLXHLCBPED-JTQLQIEISA-N 0.000 description 2
- KPTRDYONBVUWPD-UHFFFAOYSA-N naphthalen-2-ylboronic acid Chemical compound C1=CC=CC2=CC(B(O)O)=CC=C21 KPTRDYONBVUWPD-UHFFFAOYSA-N 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- JASMWYNKLTULAN-UHFFFAOYSA-N octan-3-amine Chemical compound CCCCCC(N)CC JASMWYNKLTULAN-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005586 smoking cessation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- ARYHTUPFQTUBBG-UHFFFAOYSA-N thiophen-2-ylboronic acid Chemical compound OB(O)C1=CC=CS1 ARYHTUPFQTUBBG-UHFFFAOYSA-N 0.000 description 2
- QNMBSXGYAQZCTN-UHFFFAOYSA-N thiophen-3-ylboronic acid Chemical compound OB(O)C=1C=CSC=1 QNMBSXGYAQZCTN-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- DKYRKAIKWFHQHM-UHFFFAOYSA-N (3,5-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=CC(Cl)=C1 DKYRKAIKWFHQHM-UHFFFAOYSA-N 0.000 description 1
- IBTSWKLSEOGJGJ-UHFFFAOYSA-N (3-acetamidophenyl)boronic acid Chemical compound CC(=O)NC1=CC=CC(B(O)O)=C1 IBTSWKLSEOGJGJ-UHFFFAOYSA-N 0.000 description 1
- QBMHZZHJIBUPOX-UHFFFAOYSA-N (3-aminophenyl)boronic acid;hydron;chloride Chemical compound Cl.NC1=CC=CC(B(O)O)=C1 QBMHZZHJIBUPOX-UHFFFAOYSA-N 0.000 description 1
- XDBHWPLGGBLUHH-UHFFFAOYSA-N (3-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C#N)=C1 XDBHWPLGGBLUHH-UHFFFAOYSA-N 0.000 description 1
- CHCWUTJYLUBETR-UHFFFAOYSA-N (3-ethoxyphenyl)boronic acid Chemical compound CCOC1=CC=CC(B(O)O)=C1 CHCWUTJYLUBETR-UHFFFAOYSA-N 0.000 description 1
- HJBGZJMKTOMQRR-UHFFFAOYSA-N (3-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C=O)=C1 HJBGZJMKTOMQRR-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- STZHBULOYDCZET-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-amine;hydron;dichloride Chemical compound Cl.Cl.C1CC2C(N)CN1CC2 STZHBULOYDCZET-UHFFFAOYSA-N 0.000 description 1
- PKRRNTJIHGOMRC-UHFFFAOYSA-N 1-benzofuran-2-ylboronic acid Chemical compound C1=CC=C2OC(B(O)O)=CC2=C1 PKRRNTJIHGOMRC-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- UWKQJZCTQGMHKD-UHFFFAOYSA-N 2,6-di-tert-butylpyridine Chemical compound CC(C)(C)C1=CC=CC(C(C)(C)C)=N1 UWKQJZCTQGMHKD-UHFFFAOYSA-N 0.000 description 1
- WPCSNGBKVXKBPU-UHFFFAOYSA-N 2-pyridin-3-yl-1,3-thiazole Chemical compound C1=CSC(C=2C=NC=CC=2)=N1 WPCSNGBKVXKBPU-UHFFFAOYSA-N 0.000 description 1
- FOQFGMAZUTUELM-UHFFFAOYSA-N 2-pyridin-3-yl-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC(C=2C=NC=CC=2)=N1 FOQFGMAZUTUELM-UHFFFAOYSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- SNALSZMAYDWAJA-UHFFFAOYSA-N 3-(3-fluorophenyl)benzamide Chemical compound NC(=O)C1=CC=CC(C=2C=C(F)C=CC=2)=C1 SNALSZMAYDWAJA-UHFFFAOYSA-N 0.000 description 1
- JOJCFDCFBVAXRD-UHFFFAOYSA-N 3-(3-methylphenyl)benzamide Chemical compound CC1=CC=CC(C=2C=C(C=CC=2)C(N)=O)=C1 JOJCFDCFBVAXRD-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- VOIZNVUXCQLQHS-UHFFFAOYSA-N 3-bromobenzoic acid Chemical compound OC(=O)C1=CC=CC(Br)=C1 VOIZNVUXCQLQHS-UHFFFAOYSA-N 0.000 description 1
- ZNRGSYUVFVNSAW-UHFFFAOYSA-N 3-nitrophenylboronic acid Chemical compound OB(O)C1=CC=CC([N+]([O-])=O)=C1 ZNRGSYUVFVNSAW-UHFFFAOYSA-N 0.000 description 1
- TUXYZHVUPGXXQG-UHFFFAOYSA-N 4-bromobenzoic acid Chemical compound OC(=O)C1=CC=C(Br)C=C1 TUXYZHVUPGXXQG-UHFFFAOYSA-N 0.000 description 1
- PDONIKHDXYHTLS-UHFFFAOYSA-N 4-bromothiophene-2-carbaldehyde Chemical compound BrC1=CSC(C=O)=C1 PDONIKHDXYHTLS-UHFFFAOYSA-N 0.000 description 1
- GHICCUXQJBDNRN-UHFFFAOYSA-N 4-iodobenzoic acid Chemical compound OC(=O)C1=CC=C(I)C=C1 GHICCUXQJBDNRN-UHFFFAOYSA-N 0.000 description 1
- WPCSAIACUYFJIQ-UHFFFAOYSA-N 5-(2-methoxyphenyl)furan-2-carboxamide Chemical compound COC1=CC=CC=C1C1=CC=C(C(N)=O)O1 WPCSAIACUYFJIQ-UHFFFAOYSA-N 0.000 description 1
- XIPQHWUSDHTXOO-UHFFFAOYSA-N 5-(4-chlorophenyl)furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1C1=CC=C(Cl)C=C1 XIPQHWUSDHTXOO-UHFFFAOYSA-N 0.000 description 1
- YVTQHZDUDUCGRD-UHFFFAOYSA-N 5-bromofuran-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(Br)O1 YVTQHZDUDUCGRD-UHFFFAOYSA-N 0.000 description 1
- YCNXGPMGMAKDPM-UHFFFAOYSA-N 5-bromothiophene-3-carboxylic acid Chemical compound OC(=O)C1=CSC(Br)=C1 YCNXGPMGMAKDPM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical class CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical class [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- RLCUMWFYWXYHTF-UHFFFAOYSA-N N1(C=CC=C1)OC(=[N+](C)C)N(C)C Chemical compound N1(C=CC=C1)OC(=[N+](C)C)N(C)C RLCUMWFYWXYHTF-UHFFFAOYSA-N 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- VKCLPVFDVVKEKU-UHFFFAOYSA-N S=[P] Chemical class S=[P] VKCLPVFDVVKEKU-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- AVRWEULSKHQETA-UHFFFAOYSA-N Thiophene-2 Chemical compound S1C=2CCCCCC=2C(C(=O)OC)=C1NC(=O)C1=C(F)C(F)=C(F)C(F)=C1F AVRWEULSKHQETA-UHFFFAOYSA-N 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- WOAORAPRPVIATR-UHFFFAOYSA-N [3-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(C(F)(F)F)=C1 WOAORAPRPVIATR-UHFFFAOYSA-N 0.000 description 1
- NCEXBIXMMJQMFO-UHFFFAOYSA-N [Br].BrC1=CC(=CS1)C(=O)O Chemical compound [Br].BrC1=CC(=CS1)C(=O)O NCEXBIXMMJQMFO-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000007080 aromatic substitution reaction Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000006949 cholinergic function Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- AEDZKIACDBYJLQ-UHFFFAOYSA-N ethane-1,2-diol;hydrate Chemical compound O.OCCO AEDZKIACDBYJLQ-UHFFFAOYSA-N 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- CYEFKCRAAGLNHW-UHFFFAOYSA-N furan-3-ylboronic acid Chemical compound OB(O)C=1C=COC=1 CYEFKCRAAGLNHW-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- XXGPJVZDKNCYDC-UHFFFAOYSA-N n,n'-dicyclohexylmethanediimine;hydrochloride Chemical compound Cl.C1CCCCC1N=C=NC1CCCCC1 XXGPJVZDKNCYDC-UHFFFAOYSA-N 0.000 description 1
- KIFFOBXBQBZBPM-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-methoxyphenyl)benzamide Chemical compound COC1=CC=CC=C1C1=CC=CC(C(=O)NC2C3CCN(CC3)C2)=C1 KIFFOBXBQBZBPM-UHFFFAOYSA-N 0.000 description 1
- DAWFSECLBKZUHN-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-3-bromobenzamide Chemical compound BrC1=CC=CC(C(=O)NC2C3CCN(CC3)C2)=C1 DAWFSECLBKZUHN-UHFFFAOYSA-N 0.000 description 1
- OFMXVWXJUWNVGE-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-4-bromothiophene-2-carboxamide Chemical compound BrC1=CSC(C(=O)NC2C3CCN(CC3)C2)=C1 OFMXVWXJUWNVGE-UHFFFAOYSA-N 0.000 description 1
- OOGWQHRFIFVTEZ-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-4-iodobenzamide Chemical compound C1=CC(I)=CC=C1C(=O)NC1C(CC2)CCN2C1 OOGWQHRFIFVTEZ-UHFFFAOYSA-N 0.000 description 1
- NDEVYBGGPPDEPG-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-4-pyridin-4-ylthiophene-2-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(SC=1)=CC=1C1=CC=NC=C1 NDEVYBGGPPDEPG-UHFFFAOYSA-N 0.000 description 1
- OIEAJUFPEQIZHL-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-(3-fluorophenyl)furan-2-carboxamide Chemical compound FC1=CC=CC(C=2OC(=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 OIEAJUFPEQIZHL-UHFFFAOYSA-N 0.000 description 1
- WUKDHJGFJBQDAY-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-(3-fluorophenyl)thiophene-2-carboxamide Chemical compound FC1=CC=CC(C=2SC(=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 WUKDHJGFJBQDAY-UHFFFAOYSA-N 0.000 description 1
- LCGCTFJMVXHREJ-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-(3-hydroxyphenyl)thiophene-2-carboxamide Chemical compound OC1=CC=CC(C=2SC(=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 LCGCTFJMVXHREJ-UHFFFAOYSA-N 0.000 description 1
- GALYCJSQLYPAQX-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-(3-methoxyphenyl)thiophene-2-carboxamide Chemical compound COC1=CC=CC(C=2SC(=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 GALYCJSQLYPAQX-UHFFFAOYSA-N 0.000 description 1
- IPNOSOBDTLDLNU-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-[3-(dimethylamino)phenyl]thiophene-2-carboxamide Chemical compound CN(C)C1=CC=CC(C=2SC(=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 IPNOSOBDTLDLNU-UHFFFAOYSA-N 0.000 description 1
- INHFORKYPSDFNF-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-[3-(methylamino)phenyl]thiophene-2-carboxamide Chemical compound CNC1=CC=CC(C=2SC(=CC=2)C(=O)NC2C3CCN(CC3)C2)=C1 INHFORKYPSDFNF-UHFFFAOYSA-N 0.000 description 1
- NKPRIPDEFRADKU-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-phenylthiophene-3-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(C=1)=CSC=1C1=CC=CC=C1 NKPRIPDEFRADKU-UHFFFAOYSA-N 0.000 description 1
- HXCRNIZEZKEKNY-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-pyridin-3-yl-2h-1,3-thiazole-3-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)N(C=1)CSC=1C1=CC=CN=C1 HXCRNIZEZKEKNY-UHFFFAOYSA-N 0.000 description 1
- LGYGWEZFGJYJBD-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-pyridin-3-ylfuran-2-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(O1)=CC=C1C1=CC=CN=C1 LGYGWEZFGJYJBD-UHFFFAOYSA-N 0.000 description 1
- YDOOADJCFORQJS-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-5-quinolin-8-ylthiophene-2-carboxamide Chemical compound C1=CN=C2C(C3=CC=C(S3)C(NC3C4CCN(CC4)C3)=O)=CC=CC2=C1 YDOOADJCFORQJS-UHFFFAOYSA-N 0.000 description 1
- KIFFOBXBQBZBPM-IBGZPJMESA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(2-methoxyphenyl)benzamide Chemical compound COC1=CC=CC=C1C1=CC=CC(C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 KIFFOBXBQBZBPM-IBGZPJMESA-N 0.000 description 1
- UVLJDZIZYSDTKE-FQEVSTJZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(3-methoxyphenyl)benzamide Chemical compound COC1=CC=CC(C=2C=C(C=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 UVLJDZIZYSDTKE-FQEVSTJZSA-N 0.000 description 1
- VTRZFLGHZHXPNK-FQEVSTJZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(3-methylphenyl)benzamide Chemical compound CC1=CC=CC(C=2C=C(C=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 VTRZFLGHZHXPNK-FQEVSTJZSA-N 0.000 description 1
- OOGWQHRFIFVTEZ-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-4-iodobenzamide Chemical compound C1=CC(I)=CC=C1C(=O)N[C@@H]1C(CC2)CCN2C1 OOGWQHRFIFVTEZ-ZDUSSCGKSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KCXYZMFPZHYUFO-UHFFFAOYSA-N n-methyl-n-phosphanylmethanamine Chemical compound CN(C)P KCXYZMFPZHYUFO-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- KXJJSKYICDAICD-UHFFFAOYSA-N quinolin-8-ylboronic acid Chemical compound C1=CN=C2C(B(O)O)=CC=CC2=C1 KXJJSKYICDAICD-UHFFFAOYSA-N 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000004149 tartrazine Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- YNVOMSDITJMNET-UHFFFAOYSA-N thiophene-3-carboxylic acid Chemical compound OC(=O)C=1C=CSC=1 YNVOMSDITJMNET-UHFFFAOYSA-N 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- SANWDQJIWZEKOD-UHFFFAOYSA-N tributyl(furan-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CO1 SANWDQJIWZEKOD-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0000540A SE0000540D0 (sv) | 2000-02-18 | 2000-02-18 | New compounds |
| PCT/SE2001/000329 WO2001060821A1 (en) | 2000-02-18 | 2001-02-15 | Novel biarylcarboxamides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02007543A true MXPA02007543A (es) | 2002-12-13 |
Family
ID=20278508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02007543A MXPA02007543A (es) | 2000-02-18 | 2001-02-15 | Biarilcarboxamidas novedosas. |
Country Status (33)
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0000540D0 (sv) * | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| US6486172B2 (en) | 2000-08-18 | 2002-11-26 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| AU2001284645A1 (en) * | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| AU2001282874A1 (en) * | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| US6492385B2 (en) | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| JP2004506734A (ja) * | 2000-08-21 | 2004-03-04 | ファルマシア・アンド・アップジョン・カンパニー | 疾患治療用のキヌクリド置換ヘテロアリール部分 |
| WO2002017358A2 (en) * | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists) |
| US6599916B2 (en) | 2000-08-21 | 2003-07-29 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| DE10103954B4 (de) | 2001-01-30 | 2005-10-06 | Advalytix Ag | Verfahren zur Analyse von Makromolekülen |
| PE20021019A1 (es) | 2001-04-19 | 2002-11-13 | Upjohn Co | Grupos azabiciclicos sustituidos |
| DE10120035B4 (de) | 2001-04-24 | 2005-07-07 | Advalytix Ag | Verfahren und Vorrichtung zur Manipulation kleiner Flüssigkeitsmengen auf Oberflächen |
| AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
| AR036041A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen |
| US6562816B2 (en) | 2001-08-24 | 2003-05-13 | Pharmacia & Upjohn Company | Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease |
| BR0212477A (pt) * | 2001-09-12 | 2004-08-24 | Upjohn Co | 7-aza[2.2.1] bicicloheptanos substituìdos para o tratamento de doenças |
| OA12708A (en) | 2001-10-02 | 2006-06-26 | Upjohn Co | Azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease. |
| WO2003032897A2 (en) * | 2001-10-16 | 2003-04-24 | Astrazeneca Ab | Azabicyclic compounds for the treatment of fibromyalgia syndrome |
| CA2464194A1 (en) * | 2001-10-26 | 2003-05-08 | Pharmacia & Upjohn Company | N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists |
| US6849620B2 (en) | 2001-10-26 | 2005-02-01 | Pfizer Inc | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease |
| US6919359B2 (en) | 2001-11-08 | 2005-07-19 | Pfizer Inc | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease |
| US6951868B2 (en) | 2001-11-09 | 2005-10-04 | Pfizer Inc. | Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease |
| DE10156719A1 (de) | 2001-11-19 | 2003-05-28 | Bayer Ag | Heteroarylcarbonsäureamide |
| DE10162375A1 (de) * | 2001-12-19 | 2003-07-10 | Bayer Ag | Bicyclische N-Aryl-amide |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| MXPA04007936A (es) * | 2002-02-15 | 2004-11-26 | Upjohn Co | Compuestos de aril-sustituidos para el tratamiento de enfermedades. |
| CA2476681A1 (en) * | 2002-02-19 | 2003-08-28 | Bruce N. Rogers | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
| US6894042B2 (en) | 2002-02-19 | 2005-05-17 | Pharmacia & Upjohn Company | Azabicyclic compounds for the treatment of disease |
| DE10211415A1 (de) * | 2002-03-15 | 2003-09-25 | Bayer Ag | Bicyclische N-Biarylamide |
| DE10211416A1 (de) * | 2002-03-15 | 2003-09-25 | Bayer Ag | Essig- und Propionsäureamide |
| CA2488761C (en) * | 2002-06-10 | 2011-05-31 | Bayer Healthcare Ag | 2-benzofuryl or benzothiophenyl-quinuclidinyl amides as nicotinic acetylcholine receptor inhibitors |
| US7176198B2 (en) | 2002-08-01 | 2007-02-13 | Pfizer Inc. | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| BR0317110A (pt) * | 2002-12-11 | 2005-10-25 | Pharmacia & Upjohn Co Llc | Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos |
| JP2006515023A (ja) * | 2003-01-22 | 2006-05-18 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | α−7nACh受容体完全アゴニストによる疾患処置 |
| GB0310867D0 (en) * | 2003-05-12 | 2003-06-18 | Novartis Ag | Organic compounds |
| US20050129610A1 (en) * | 2003-06-24 | 2005-06-16 | Johns Hopkins University | Imaging agents and methods of imaging alpha7-nicotinic cholinergic receptor |
| DE10334724A1 (de) * | 2003-07-30 | 2005-02-24 | Bayer Healthcare Ag | N-Biarylamide |
| JP2007515481A (ja) * | 2003-12-22 | 2007-06-14 | アストラゼネカ・アクチエボラーグ | ニコチン性アセチルコリンレセプターリガンド |
| WO2005061494A1 (en) * | 2003-12-22 | 2005-07-07 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| RU2367665C2 (ru) * | 2004-02-04 | 2009-09-20 | НьюроСёрч А/С | Диазабициклические арильные производные в качестве лигандов никотиновых ацетилхолиновых рецепторов |
| AR049401A1 (es) | 2004-06-18 | 2006-07-26 | Novartis Ag | Aza-biciclononanos |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| GB0424564D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| EP1910328A1 (en) * | 2005-06-29 | 2008-04-16 | AstraZeneca AB | Thiophene-2-carboxamide derivatives as alpha 7 nicotinic receptor modulators |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| EP3150589A1 (en) | 2007-06-08 | 2017-04-05 | MannKind Corporation | Ire-1a inhibitors |
| WO2009013535A1 (en) * | 2007-07-23 | 2009-01-29 | Astrazeneca Ab | 2-azabicyclo(2.2.2)octane derivatives as modulators of the glycine transporter i receptor |
| SA08290475B1 (ar) * | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| EP2488520B1 (en) | 2009-10-13 | 2015-09-02 | Merck Sharp & Dohme B.V. | Condensed azine-derivatives for the treatment of diseases related to the acetylcholine receptor |
| CA3057923A1 (en) | 2010-05-17 | 2011-11-24 | Patricia Oliver-Shaffer | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate |
| KR101928505B1 (ko) | 2011-01-28 | 2018-12-12 | 에스케이바이오팜 주식회사 | 피리돈 유도체 및 이를 포함하는 약학적 조성물 |
| KR101925971B1 (ko) * | 2011-01-28 | 2018-12-06 | 에스케이바이오팜 주식회사 | 피리돈 유도체 및 이를 포함하는 약학적 조성물 |
| GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| JP6263469B2 (ja) | 2011-07-15 | 2018-01-17 | ノバルティス アーゲー | アザ二環式ジ−アリールエーテルの塩およびその製造方法またはその前駆体の製造方法 |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| MX358512B (es) | 2012-05-08 | 2018-08-24 | Forum Pharmaceuticals Inc | Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva. |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| US9593106B2 (en) | 2013-02-07 | 2017-03-14 | Heptares Therapeutics Limited | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists |
| CN105324372B (zh) | 2013-06-21 | 2018-03-06 | 武田药品工业株式会社 | 作为前动力蛋白受体调节剂的1‑磺酰基哌啶衍生物 |
| GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
| GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
| FI20145054L (fi) * | 2014-01-21 | 2015-07-22 | Tellabs Oy | Tiedonsiirtoverkon verkkoelementti |
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| KR101623138B1 (ko) | 2014-10-28 | 2016-05-20 | 한국원자력연구원 | 베타 아밀로이드 플라크 검출 및 알츠하이머 질환 진단 또는 치료용 조성물 |
| GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
| GB201619514D0 (en) | 2016-11-18 | 2017-01-04 | Takeda Pharmaceuticals Co | Novel compounds |
| JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1416872A (en) * | 1972-03-10 | 1975-12-10 | Wyeth John & Brother Ltd | 4-aminoquinoline derivatives |
| FI791491A7 (fi) * | 1979-05-10 | 1981-01-01 | Kopo Konepohja Oy | Puun palahakkuri. |
| FR2529548A1 (fr) * | 1982-07-02 | 1984-01-06 | Delalande Sa | Nouveaux derives de l'amino-3 quinuclidine, leur procede et leur application en therapeutique |
| US4605652A (en) * | 1985-02-04 | 1986-08-12 | A. H. Robins Company, Inc. | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes |
| US4863919A (en) * | 1988-02-01 | 1989-09-05 | A. H. Robins Company, Incorporated | Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes |
| ATE125808T1 (de) * | 1990-08-31 | 1995-08-15 | Nippon Shinyaku Co Ltd | Indolederivate und ihre verwendung als serotonin- antagoniste. |
| JPH04247081A (ja) * | 1991-02-01 | 1992-09-03 | Takeda Chem Ind Ltd | 5員複素環酸アミド類 |
| SE9904176D0 (sv) | 1999-11-18 | 1999-11-18 | Astra Ab | New use |
| SE0000540D0 (sv) * | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| FR2809731B1 (fr) | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | Derives de 1,4-diazabicyclo-[3.2.2] nonane-pheylisoxazole, leur preparation et leur application en therapeutique |
| FR2809732B1 (fr) | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | DERIVES DE 4(-2-PHENYLTHIAZOL-5-yl)-1,4-DIAZABICYCLO-[3.2.2] NONANE, LEUR PREPARATION ET LEUR APPLICATION ENTHERAPEUTIQUE |
| FR2809730B1 (fr) | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | Derives de 1,4-diazabicyclo[3.2.2] nonanebenzoxazole, -benzothiazole et -benzimidazole, leur preparation et leur application therapeutique |
| TW593223B (en) | 2000-06-20 | 2004-06-21 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists |
| US6492385B2 (en) * | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| AU2001282874A1 (en) | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| AU2001284645A1 (en) | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| US6486172B2 (en) | 2000-08-18 | 2002-11-26 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| JP2004506734A (ja) | 2000-08-21 | 2004-03-04 | ファルマシア・アンド・アップジョン・カンパニー | 疾患治療用のキヌクリド置換ヘテロアリール部分 |
| US6599916B2 (en) | 2000-08-21 | 2003-07-29 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| WO2002017358A2 (en) | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists) |
| DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
| WO2002044176A1 (en) | 2000-12-01 | 2002-06-06 | Neurosearch A/S | 3-substituted quinuclidines and their use as nicotinic agonists |
| US20020086871A1 (en) | 2000-12-29 | 2002-07-04 | O'neill Brian Thomas | Pharmaceutical composition for the treatment of CNS and other disorders |
| JP2007515481A (ja) * | 2003-12-22 | 2007-06-14 | アストラゼネカ・アクチエボラーグ | ニコチン性アセチルコリンレセプターリガンド |
| US7396830B2 (en) * | 2005-10-04 | 2008-07-08 | Bristol-Myers Squibb Company | Piperazine amidines as antiviral agents |
-
2000
- 2000-02-18 SE SE0000540A patent/SE0000540D0/xx unknown
-
2001
- 2001-02-12 AR ARP010100628A patent/AR029798A1/es unknown
- 2001-02-15 AU AU32594/01A patent/AU782693B2/en not_active Ceased
- 2001-02-15 SK SK1179-2002A patent/SK11792002A3/sk unknown
- 2001-02-15 DK DK01904770T patent/DK1259508T3/da active
- 2001-02-15 DE DE60100996T patent/DE60100996T2/de not_active Expired - Fee Related
- 2001-02-15 RU RU2002118302/04A patent/RU2263114C2/ru active
- 2001-02-15 PL PL357565A patent/PL202044B1/pl not_active IP Right Cessation
- 2001-02-15 CN CNB018049362A patent/CN100345847C/zh not_active Expired - Fee Related
- 2001-02-15 CA CA002397233A patent/CA2397233A1/en not_active Abandoned
- 2001-02-15 BR BR0108456-9A patent/BR0108456A/pt not_active Application Discontinuation
- 2001-02-15 UA UA2002075475A patent/UA73540C2/uk unknown
- 2001-02-15 WO PCT/SE2001/000329 patent/WO2001060821A1/en not_active Ceased
- 2001-02-15 JP JP2001560205A patent/JP4084570B2/ja not_active Expired - Fee Related
- 2001-02-15 HU HU0301069A patent/HUP0301069A3/hu unknown
- 2001-02-15 EE EEP200200459A patent/EE05149B1/xx not_active IP Right Cessation
- 2001-02-15 IL IL15054401A patent/IL150544A0/xx unknown
- 2001-02-15 KR KR1020027010731A patent/KR100769394B1/ko not_active Expired - Fee Related
- 2001-02-15 AT AT01904770T patent/ATE252099T1/de not_active IP Right Cessation
- 2001-02-15 TR TR2004/00072T patent/TR200400072T4/xx unknown
- 2001-02-15 PT PT01904770T patent/PT1259508E/pt unknown
- 2001-02-15 EP EP01904770A patent/EP1259508B1/en not_active Expired - Lifetime
- 2001-02-15 ES ES01904770T patent/ES2208556T3/es not_active Expired - Lifetime
- 2001-02-15 NZ NZ520094A patent/NZ520094A/en unknown
- 2001-02-15 MX MXPA02007543A patent/MXPA02007543A/es active IP Right Grant
- 2001-02-15 CZ CZ20022787A patent/CZ20022787A3/cs unknown
- 2001-02-16 MY MYPI20010711A patent/MY123580A/en unknown
- 2001-02-16 CO CO01012482A patent/CO5280046A1/es not_active Application Discontinuation
-
2002
- 2002-04-15 US US10/123,856 patent/US7001914B2/en not_active Expired - Fee Related
- 2002-07-09 ZA ZA200205479A patent/ZA200205479B/xx unknown
- 2002-08-02 BG BG106977A patent/BG106977A/bg unknown
- 2002-08-08 IS IS6492A patent/IS6492A/is unknown
- 2002-08-16 NO NO20023917A patent/NO20023917L/no not_active Application Discontinuation
-
2006
- 2006-01-05 US US11/325,787 patent/US7214688B2/en not_active Expired - Fee Related
-
2007
- 2007-03-01 US US11/680,930 patent/US7491734B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02007543A (es) | Biarilcarboxamidas novedosas. | |
| ES2316848T3 (es) | Biaril diazabicicloalcano amidas como agonistas de nicotinicos de la acetilcolina. | |
| AU784400B2 (en) | New use and novel N-azabicyclo-amide derivatives | |
| HK1050007B (en) | Novel biarylcarboxamides | |
| HK1077571B (en) | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |